Breaking News

Turing Acquires U.S. Marketing Rights to Daraprim

Also raises $90 million to invest in developing treatments for serious diseases across a broad range of therapeutic areas

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Turing Pharmaceuticals AG has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis. According to terms of the deal, Turing will acquire all U.S. marketing rights and assume all regulatory responsibilities, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters